in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836.
Lyon, France and Liège, Belgium – September 16, 2025 –
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its Phase 2b clinical trial (NCT05569239) evaluating OVX836, the company’s broad-spectrum influenza A vaccine candidate.
OVX836 has previously demonstrated favorable safety, immunogenicity, and cross-reactivity results in multiple Phase 1 and Phase 2a studies, together with promising signals of efficacy (exploratory endpoints). This Phase 2b trial marks the first large-scale evaluation of OVX836’s efficacy in a large population, representing a key step forward in Osivax’ mission to develop a novel best-in-class influenza vaccine.
